Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Complex percutaneous coronary intervention (PCI) increases ischemic risk, often managed with dual antiplatelet therapy (DAPT).
• High bleeding risk (HBR) complicates DAPT duration decisions after PCI.
• Balancing ischemic and bleeding risks is crucial for optimal patient outcomes.

Purpose of the Study:

• To evaluate the impact of DAPT duration on clinical outcomes in patients undergoing complex PCI.
• To assess how ischemic and bleeding risks influence the effectiveness of DAPT strategies.
• To determine whether PCI complexity or bleeding risk should guide DAPT duration.

Main Methods:

• Analysis of 14,963 patients from 8 randomized trials, with a focus on 3,118 undergoing complex PCI.
• Stratification of patients based on PCI complexity (≥3 stents, ≥3 lesions, etc.) and bleeding risk (PRECISE-DAPT score ≥25).
• Randomized allocation to different DAPT durations and evaluation of ischemic and bleeding events.

Main Results:

• Complex PCI was associated with higher ischemic event rates but not bleeding events.
• Long-term DAPT reduced ischemic events in non-HBR patients with both complex and non-complex PCI.
• Long-term DAPT did not benefit HBR patients, and increased bleeding risk in this group, irrespective of PCI complexity.

Conclusions:

• Patients with complex PCI benefit from long-term DAPT only if they do not have high bleeding risk.
• Bleeding risk assessment is paramount in guiding DAPT duration decisions, particularly in HBR patients.
• Clinical decision-making for DAPT duration should prioritize bleeding risk over ischemic risk when these factors are discordant.